Literature DB >> 11896340

DNA-based typing of blood groups for the management of multiply-transfused sickle cell disease patients.

Lilian Castilho1, Maria Rios, Celso Bianco, Jordão Pellegrino, Fernando L Alberto, Sara T O Saad, Fernando F Costa.   

Abstract

BACKGROUND: The usefulness of DNA genotyping for RBC antigens as a tool for the management of multiply-transfused patients with sickle cell disease (SCD) to overcome the limitations of hemagglutination assays was evaluated. STUDY DESIGN AND METHODS: Blood samples from 40 multiply-transfused SCD patients were studied by hemagglutination and by PCR-RFLP for antigens or genes in the Rh (D, C/c, E/e), Kell, Kidd, and Duffy systems.
RESULTS: Discrepancies were found between hemaglutination and DNA typing test results in six patients: two were discrepant in Rh typing (one was D- by hemagglutination and RhD by DNA, and one was E+e- and RhEe by DNA), two were discrepant in Duffy typing [both were Fy(a+b-) and Fy(b)/Fy(b) by DNA], and four were discrepant in Kidd typing [Jk(a+b+) and Jk(b)/Jk(b) by DNA; two of these samples were also discrepant in Duffy]. Stored segments from blood units that had been recently transfused to these six recipients were phenotyped, confirming that the transfused RBCs were the source of the discrepancy between genotype and phenotype.
CONCLUSION: DNA typing of blood groups by PCR-RFLP in peripheral blood WBCs contributes to the management of transfusions in SCD patients by allowing a more accurate selection of donor units.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11896340     DOI: 10.1046/j.1537-2995.2002.00029.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  19 in total

1.  Blood group genotyping facilitates transfusion of beta-thalassemia patients.

Authors:  Lilian Castilho; Maria Rios; Jordão Pellegrino; Sara T O Saad; Fernando F Costa
Journal:  J Clin Lab Anal       Date:  2002       Impact factor: 2.352

2.  Benefits of blood group genotyping in multi-transfused patients from the south of Brazil.

Authors:  Gláucia Andréia Soares Guelsin; Ana Maria Sell; Lilian Castilho; Viviane Lika Masaki; Fabiano Cavalcante Melo; Margareth Naomi Hashimoto; Tatiana Takahashi Higa; Loide Souza Hirle; Jeane Eliete Laguila Visentainer
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

3.  Duffy genotyping facilitates transfusion therapy.

Authors:  Carlos Cotorruelo; Claudia Biondi; Liliana Racca; Silvia García Borrás; Amelia Racca
Journal:  Clin Exp Med       Date:  2009-02-19       Impact factor: 3.984

4.  Rapid, single-subject genotyping to predict red blood cell antigen expression.

Authors:  S L Slezak; S Adams; H Lee-Stroka; J E Martin; L Caruccio; D F Stroncek
Journal:  Immunohematology       Date:  2008

Review 5.  Pathogenesis and mechanisms of antibody-mediated hemolysis.

Authors:  Willy A Flegel
Journal:  Transfusion       Date:  2015-07       Impact factor: 3.157

6.  Applying molecular immunohaematology to regularly transfused thalassaemic patients in Thailand.

Authors:  Pairaya Rujirojindakul; Willy A Flegel
Journal:  Blood Transfus       Date:  2013-10-03       Impact factor: 3.443

Review 7.  Molecular basis of the Duffy blood group system.

Authors:  Gabriela Höher; Marilu Fiegenbaum; Silvana Almeida
Journal:  Blood Transfus       Date:  2017-01-30       Impact factor: 3.443

8.  Why do we use serological blood group phenotype determination in chronically transfused patients?

Authors:  Franz F Wagner
Journal:  Blood Transfus       Date:  2013-12-11       Impact factor: 3.443

Review 9.  Optimized Antigen-Matched in Sickle Cell Disease Patients: Chances and Challenges in Molecular Times - the Brazilian Way.

Authors:  Lilian Castilho; Carla Luana Dinardo
Journal:  Transfus Med Hemother       Date:  2018-07-06       Impact factor: 3.747

10.  Molecular matching for Rh and K reduces red blood cell alloimmunisation in patients with myelodysplastic syndrome.

Authors:  Gláucia A S Guelsin; Camila Rodrigues; Jeane E L Visentainer; Paula De Melo Campos; Fabíola Traina; Simone C O Gilli; Sara T O Saad; Lilian Castilho
Journal:  Blood Transfus       Date:  2014-06-12       Impact factor: 3.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.